Endosymbiotic Wolbachia of parasitic filarial nematodes as drug targets
|
|
- Henry Mason
- 5 years ago
- Views:
Transcription
1 Review Article Indian J Med Res 122, September 2005, pp Endosymbiotic Wolbachia of parasitic filarial nematodes as drug targets Ramakrishna U. Rao Department of Internal Medicine, Infectious Diseases Division,Washington University School of Medicine, St. Louis, MO, USA Received October 20, 2004 The parasitic nematodes Wuchereria bancrofti, Brugia malayi and B. timori cause a dreadful disease in humans known as lymphatic filariasis, which afflicts more than 120 million people worldwide. As per recent epidemiologic estimates on prevalence of W. bancrofti and B. malayi, about 428 million people are at risk, with 28 million microfilaria carriers and 21 million clinical cases spread out in 13 States and 5 Union Territories of India. The Indian subcontinent that comprises Bangladesh, India, Maldives, Nepal and Sri Lanka harbours 50 per cent of the world s lymphatic filarial disease burden. Recently, an endobacterium of Wolbachia species that belongs to the family Rickettsiaceae was found in all life cycle stages of these nematodes and the transmission is exclusively vertical through the embryonic stages of the female worms. People with filariasis have been exposed to these Wolbachia bacteria or their proteins by the natural killing of parasites. Wolbachia have also been identified occasionally in body fluids of infected patients. Evidence suggests that these Wolbachia are mutualistic symbionts and can be cured from the nematodes by several antibiotics having antirickettsial properties. Treatment of nematodes with tetracyclines affect Wolbachia and they get cleared from worm tissues; and this elimination causes reproductive abnormalities in worms and affect worm s embryogenesis, resulting in sterility. Although it is impractical, prolonged treatment with doxycycline significantly reduces the numbers of microfilaria in circulation, which is an important strategy to control transmission of filariasis by mosquito vectors. In this review, the current knowledge of Wolbachia as a drug target and potential ways to reduce the infection through anti-wolbachia treatments is discussed. Key words Antibiotics - Brugia malayi - diethylcarbamazine - doxycycline - embryogenesis - endobacteria - filariasis - Onchocerca volvulus - rickettsia - Wolbachia - Wuchereria bancrofti Biology of filarial Wolbachia Wolbachia of filarial nematodes (Fig.) are the obligate intracellular alpha-proteobacteria and have some resemblances with insect Wolbachia. They were first found in hypodermal tissues of lateral chords, uterine wall and in embryos of filarial nematodes (Figs 199 A, B), embedded as single or multiple organisms in host-derived vacuoles. They attain different shapes (oval, round or rod- shaped) and are µm in size. The body is covered with a double membrane enclosing the cytoplasm rich in dense ribosomes (Fig. C). In late 1970s, two groups first identified these endobacteria in filarial worms and speculated that
2 Filarial worm -M (~ cm) Filarial worm -Y (~ cm) Filarial Wolbachia (~ µm) Fig. Adult Brugia malayi filarial nematode worms (A & B) and a section of female worm s hypodermis under transmission electron microscopy showing (arrow) Wolbachia endobacteria (C). Magnifications, 10x (A, B). Scale bars, 1 cm (A, B) and 1µm (C). 200 INDIAN J MED RES, SEPTEMBER 2005
3 antibiotics could be used to treat filarial infections 1-3. All life cycle stages of filarial worms are infected with these bacteria, but the intensity of the infections varies between the life cycle stages 4,5, and appears that they have their own developmental life cycle within the worms which is yet to be clearly defined. Several filarial nematodes have been shown to contain these bacteria 6,7 and, interestingly, only a few species (for example: Loa loa, Acanthocheilonema viteae, Setaria equina and Onchocerca flexuosa) do not carry these bacteria 7-9. It is common in several other bacterial infections, that they can crossover from one host to another. Studies suggest that Wolbachia in filarial nematodes have coexisted for several million years and have not crossed over from their intermediate hosts (mosquitos for example) recently 10,11. However, loss of Wolbachia across the nematode family was reported during their evolution 7. Identification of new molecules in drug discovery research against filarial nematodes was boosted by the observation that Wolbachia can be used as a drug target and thus hold great promise towards therapeutic options available for filariasis treatment. Wolbachia as a target for therapy in animal models We and others 12,13 have shown that antibiotics active against Rickettsiaceae, particularly the tetracyclines, rifampicin and chloramphenicol, were effective in reducing the filarial larval molt (from L3 to L4) and their development in vitro. In contrast, effect of tetracycline analogues lacking antirickettsial properties also affected larval molting indicating that the drug might have other pharmacological effects on worms 14. In Brugia infected animals, tetracycline was prophylactic and affected the molting of infective larvae 15-17, and caused distortion of male/female sexratios 15. Sex-ratio bias by Wolbachia has a positive influence on insect population. Accordingly, Wolbachia may produce sex-ratio distortion during nematode development as well. This scenario would have profound implications in filarial biology as more females survive to produce millions of microfilariae and the role of males is restricted to reproduction. Antibiotics also affect adult filarial worms in vitro by reducing their ability to produce microfilariae and their viability 18. Several reports have shown effects of antibiotics on filarial nematodes in experimental RAO: WOLBACHIA AS TARGETS FOR THERAPY 201 animal models 16,17, More importantly members of tetracycline family (tetracycline, oxytetracycline, doxycycline, and minocycline) were found to be effective against worms. These antibiotics also affect Wolbachia after treatment Modes of action of these antibiotics are generally on bacterial RNA polymerases, protein synthesis, and other processes, and these agents may affect similar pathways in both worms and their Wolbachia. In several nematode worm infections these antibiotics have multiple effects on worm growth and development; worm fertility (particularly female worm embryogenesis) and worm survival, with evidence suggesting that prolonged treatment can be detrimental to worms 19,21. Moreover, when microfilaraemic animals were treated, their microfilarial numbers were considerably reduced in the circulation 19. In contrast, in animals infected with aposymbiotic A. viteae worms, which do not carry these bacteria, similar long-term treatment had no effect on worm biology and development 19, suggesting that these bacteria play a very important role in the growth and reproduction of the filarial worms that harbour them. The combination studies with rifampicin in animal models have been found promising to achieve acceptable short-term regimen plans with doxycycline 24. Interestingly, in addition to anti-wolbachia properties 18-23, tetracyclines markedly affected the normal embryogenesis profiles by causing damage and degeneration of intrauterine embryos 18-23,25. Polymerase chain reaction (PCR) assay also confirmed the clearance of Wolbachia DNA after prolonged therapy 20,23. The reduction or clearance of bacterialspecific hsp60 and Wolbachia surface protein (WSP) as determined by immunohistochemical staining indicated the absence or clearance of Wolbachia in treated worms 20,26. Wolbachia as a target of therapy against pathogenic human filarial infections The availability of safe drug doxycycline has encouraged clinical investigators to test their hypothesis that elimination of Wolbachia is beneficial in reducing the human filarial infections. The first clinical trials were done in people having onchocerciasis infections. A 6 wk course of daily doxycycline treatment (100 mg/day) depleted Wolbachia in worms, and caused extensive
4 202 INDIAN J MED RES, SEPTEMBER 2005 degeneration of embryos by 4 months posttreatment 27. The worms became sterile after the loss of Wolbachia, and infected individuals also had significantly fewer or no microfiladermia 27. The combination therapy with doxycycline and ivermectin also remarkably reduced microfiladermia following reductions in Wolbachia in worms 28,29. Similar effects were observed in W. bancrofti- infected patients after multiple doses of doxycycline (200 mg/day for 6 wk) 30. In this study, patients were treated with doxycycline followed by a single dose of ivermectin. Doxycycline treatment alone reduced Wolbachia numbers (96%) after 4 months of treatment, followed by 99 per cent reductions in number of microfilariae by one year of treatment. It would be interesting to see whether Wolbachia can repopulate in these worms after cessation of antibiotic therapy. Additional studies are needed to effectively measure macrofilaricidal activity of these drugs in such clinical studies. Interestingly, doxycycline treatment showed no effect on Loa loa (free of Wolbachia) infections in humans 31. Despite this demonstrated efficacy, multi-dose antibiotic therapy and their mass treatment regimens remain impractical especially in children and pregnant women 32. Therefore, the efficacy of short-term antibiotic treatments along with antifilarial drug combinations such as diethylcarbamazine (DEC) and albendazole in various endemic countries remains to be tested. Other than doxycycline treatment studies in selective populations carrying onchocerciasis, loaisis, or lymphatic filariasis 27-31, no clinical trials with this potent antibiotic has been reported in other endemic areas. Therefore, it is still premature to have a consensus regarding the effective universal dosage and duration of treatment for either microfilaria clearance or adult worm sterility. Moreover, the results of treatment may be affected by the immunological status of the host, age, host susceptibility and total worm burden. The filarial Wolbachia genome sequencing has been recently completed 33,34 and several new targets necessary for the bacteria are being identified. These might lead to investigate a new class of anti-wolbachia drugs that benefit filarial chemotherapy research (B. Slatko & J. Foster, personal communication). Perspective Human filariasis continued to be a major public health problem in parts of Indian subcontinent and other tropical areas of the world as a vector borne communicable disease The current antifilarial therapies are restricted to DEC or ivermectin in combination with albendazole Identification of new parasite molecules, biological targets (for example Wolbachia) and lead compounds against them are under way to minimize or control filariasis. The results emerged from experimental animal models and limited human studies are very promising; and targeting Wolbachia might be a strategic new approach to treat filariasis. This concept has been extensively reviewed recently More potent prophylactic antibiotic drugs or antibacterial agents in eliminating Wolbachia followed by parasites may be identified within pharmaceutical research platforms. For example, tigecycline (Wyeth Pharmaceuticals), an injectable class of tetracycline derivative that inhibits bacterial protein synthesis and cell growth which is under clinical trials can be tested against experimental filarial infections 46. Another promising approach, exploiting novel drug delivery such as liposomes, is based on the positive modulation of pharmacokinetics of drugs Incorporation of potent antibiotics into liposomes can consequently increase bioavailability and prolonged drug circulation time, usually allows for lowering of the dosage, and hence diminish adverse toxicities associated with therapy Antibiotics also have anti-inflammatory properties and therefore, it is possible to reduce posttreatment reactions (for example, ocular lesions in onchocerciasis and Mazzotti reactions) by administering these before standard antifilarial therapy. Targeting inclusion bodies of several pathogenic protozoans has always been an area of interest to develop novel therapeutics Similarly, the evidence presented so far with filarial Wolbachia strongly suggests that these worm-specific endobacteria emerge as one of the targets for reducing worm burden, fertility and transmission. Because of drug resistance and possible toxicity, general antibiotic use is not an option for widespread use. More research is needed to explore new biochemical pathways in Wolbachia life cycle that
5 are important for parasites to survive and new enzymes involved in Wolbachia growth and development; and once identified, their inhibitors might be the silver bullets to use in filarial therapy. References 1. McLaren DJ, Worms M, Laurence B, Simpson M. Microorganisms in filarial larvae (Nematoda). Tran R Soc Trop Med Hyg 1975; 69 : Kozek W. Transovarially-transmitted intracellular microorganisms in adult and larval stages of Brugia malayi. J Parasitol 1977; 63 : Kozek W, Marroquin H. Intracytoplasmic bacteria in Onchocerca volvulus. Am J Trop Med Hyg 1977; 26 : McGarry HF, Egerton GL, Taylor MJ. Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayi. Mol Biochem Parasitol 2004; 135 : Fenn K, Blaxter M. Quantification of Wolbachia bacteria in Brugia malayi through the nematode lifecycle. Mol Biochem Parasitol 2004; 137 : Taylor MJ, Hoerauf A. Wolbachia bacteria of filarial nematodes. Parasitol Today 1999; 15 : Casiraghi M, Bain O, Guerrero R, Martin C, Pocacqua V, Gardner SL, et al. Mapping the presence of Wolbachia pipientis on the phylogeny of filarial nematodes: evidence for symbiont loss during evolution. Int J Parasitol 2004; 34 : Büttner DW, Wanji S, Bazzocchi C, Bain O, Fischer P. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa. Filaria J 2003; 9 : Chirgwin SR, Porthouse KH, Nowling JM, Klei TR. The filarial endosymbiont Wolbachia sp. is absent from Setaria equina. J Parasitol 2002; 88 : Bandi C, Anderson TJC, Genchi C, Blaxter ML. Phylogeny of Wolbachia in filarial nematodes. Proc R Soc London B Biol Sci 1998; 265 : Casiraghi M, Anderson TJC, Bandi C, Bazzocchi C, Genchi C. A phylogenetic analysis of filarial nematodes: comparison with the phylogeny of Wolbachia endosymbionts. Parasitology 2001; 122 : Smith HL, Rajan TV. Tetracycline inhibits development of the infective-stage larvae of filarial nematodes in vitro. Exp Parasitol 2000; 95 : Rao R, Weil GJ. In vitro effects of antibiotics on Brugia malayi worm survival and reproduction. J Parasitol 2002; 88 : Rajan TV. Relationship of anti-microbial activity of tetracyclines to their ability to block the L3 to L4 molt of RAO: WOLBACHIA AS TARGETS FOR THERAPY 203 the human filarial parasite Brugia malayi. Am J Trop Med Hyg 2004; 71 : Casiraghi M, McCall JW, Simoncini L, Kramer LH, Sacchi L, Genchi C, et al. Tetracycline treatment and sex-ratio distortion: a role for Wolbachia in the moulting of filarial nematodes? Int J Parasitol 2002; 32 : Bosshardt SC, McCall JW, Coleman SU, Jones KL, Petit TA, Klei TR. Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus). J Parasitol 1993; 79 : McCall JW, Jun JJ, Bandi C. Wolbachia and the antifilarial properties of tetracycline. An untold story. Italian J Zool 1999; 66 : Rao R, Moussa H, Weil GJ. Brugia malayi: Effects of antibacterial agents on larval viability and development in vitro. Exp Parasitol 2002; 101 : Hoerauf A, Nissen-Pàehle, K, Schmetz C, Henkle-Dührsen, K, Blaxter, M L, Büttner D W, et al. Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility. J Clin Invest 1999; 103 : Hoerauf A, Volkmann L, Nissen-Pàehle, K, Schmetz C, Autenrieth I, Büttner DW, et al. Targetting of Wolbachia endobacteria in Litomosoides sigmodontis: comparison of tetracyclines with chloramphenicol, macrolides and ciprofloxin. Trop Med Int Health 2000; 5 : Langworthy NG, Renz A, Meckenstedr U, Henkle-Dührsen K, Bronsvoort M, Tanya VN, et al. Macrofilaricidal activity of tetracycline against the filarial nematode, Onchocerca ochengi: elimination of Wolbachia precedes worm death and suggests a dependent relationship. Proc R Soc London Series B 2000; 267 : Townson S, Hutton D, Siemienska J, Hollick L, Scanlon, T, Tagboto SK, et al. Antibiotics and Wolbachia in filarial nematodes: antifilarial activity of rifampicin, oxytetracycline and chloramphenicol against Onchocerca gutturosa, Onchocerca lienalis and Brugia pahangi. Ann Trop Med Parasitol 2000; 94 : Bandi C, McCall J W, Genchi C, Corona S, Venco L, Sacchi L. Effects of tetracycline on the filarial worms Brugia pahangi and Dirofilaria immitis and their bacterial endosymbionts Wolbachia. Int J Parasitol 1999; 29 : Volkmann L, Fischer K, Taylor M, Hoerauf A. Antibiotic therapy in murine filariasis (Litomosoides carinii): Comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Trop Med Int Health 2003; 8 : Sacchi L, Corona S, Kramer L, Calvi L, Casiraghi M, Franceschi A. Ultrastructural evidence of the degenerative events occurring during embryogenesis of the filarial nematode Brugia pahangi after tetracycline treatment. Parasitologia 2003; 45 :
6 204 INDIAN J MED RES, SEPTEMBER Kramer LH, Passeri B, Corona S, Simoncini L, Casiraghi M. Immunohistochemical/immunogold detection and distribution of the endosymbiont Wolbachia of Dirofilaria immitis and Brugia pahangi using a polyclonal antiserum raised against WSP (Wolbachia surface protein). Parasitol Res 2003; 89 : Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fliescher B, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355 : Hoerauf A, Mand S, Adjei O, Fleischer B, Büttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfiladermia after ivermectin treatment. Lancet 2001; 357 : Hoerauf A, Mand S, Volkmann L, Büttner M, Marfo- Debrekyei Y, Taylor M, et al. Doxycycline in the treatment of human onchocerciasis: Kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003; 5 : Hoerauf A, Mand S, Fischer K, Kruppa T, Marfo-Debrekyei Y, Debrah AY, et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Med Microbiol Immunol 2003; 192 : Brouqui P, Fournier PE, Raoult D. Doxycycline and eradication of microfilaremia in patients with loiasis. Emerg Infect Dis 2001; 7 : Walgate R. Could antibiotics cure river blindness? Bull World Health Organ 2002; 80 : accessed on October Foster J, Ganatra M, Kamal I, Ware J, Makarova K, Ivanova N, et al. The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematode. PLoS Biol 2005; 3 : e Devaney E, Yazdanbakhsh M. Prospects and challenges in lymphatic filariasis. Parasite Immunol 2001; 23 : Freeing the World of LF: A call to action. 3rd meeting of the Global Alliance to Eliminate Lymphatic Filariasis. March 2004; Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003; 19 : Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999; 15 : Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med 2002; 347 : Melrose WD. Chemotherapy for lymphatic filariasis: progress but not perfection. Expert Rev Anti Infect Ther 2003; 1 : Sabesan S, Ravi R, Das PK. Elimination of lymphatic filariasis in India. Lancet Infect Dis 2005; 5 : Rajendran R, Sunish IP, Mani TR, Munirathinam A, Abdullah SM, Arunachalam N, et al. Impact of two annual single-dose mass drug administrations with diethylcarbamazine alone or in combination with albendazole on Wuchereria bancrofti microfilaraemia and antigenaemia in south India. Trans R Soc Trop Med Hyg 2004; 98 : Taylor MJ, Hoerauf A. A new approach to the treatment of filariasis. Curr Opin Infect Dis 2001; 14 : Hoerauf A, Adjei O, Büttner DW. Antibiotics for the treatment of onchocerciasis and other filarial infections. Curr Opin Investig Drugs 2002; 3 : Rao R. Wolbachia in worms: endosymbiont of parasitic filarial nematodes. Recent Res Develop Ex Med TransWorld Research Network Publications (Kerala, India). 2004; 1 : Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49 : Sangare L, Morisset R, Omri A, Ravaoarinoro M. Incorporation rates, stabilities, cytotoxicities and release of liposomal tetracycline and doxycycline in human serum. J Antimicrob Chemother 1998; 42 : Sangare L, Morisset R, Ravaoarinoro M. In vitro antichlamydial activities of free and liposomal tetracycline and doxycycline. J Med Microbiol 1999; 48 : Bakker-Woudenberg IA, Schiffelers RM, Storm G, Becker MJ, Guo L. Long-circulating sterically stabilized liposomes in the treatment of infections. Methods Enzymol 2005; 391 : McFadden GI, Roos DS. Apicomplexan plastids as drug targets. Trends Microbiol 1999; 7 : Wilson RJ. Parasite plastids: approaching the endgame. Biol Rev Camb Philos Soc 2005; 80 : Reprint requests: Dr R.U. Rao, Department of Internal Medicine, Infectious Diseases Division, Washington University School of Medicine, 660 S Euclid Ave, St. Louis, MO 63110, USA rrao@wustl.edu
Canine and feline heartworm infections remain a
Article 3 CREDITS The Emerging Role of Wolbachia Species in Heartworm Disease Kristen Frank, DVM R. Dennis Heald, DVM, DACVIM Gulf Coast Veterinary Specialists Houston, Texas Abstract: Heartworm disease
More informationFrom macrocyclic lactones back to tetracyclines: new targets for the antiparasitic treatment in animals and humans
From macrocyclic lactones back to tetracyclines: new targets for the antiparasitic treatment in animals and humans Claudio Genchi Ordinario di Malattie Parassitarie Università degli Studi di Milano Medicinal
More informationMAJOR ARTICLE. Doxycycline Treatment in Brugian Filariasis CID 2008:46 (1 May) 1385
MAJOR ARTICLE Doxycycline Treatment of Brugia malayi Infected Persons Reduces Microfila emia and Adverse Reactions after Diethylcarbamazine and Albendazole Treatment Taniawati Supali, 1 Yenny Djuardi,
More informationDrug therapy of Filariasis. Dr. Shareef sm Asst. professor pharmacology
Drug therapy of Filariasis Dr. Shareef sm Asst. professor pharmacology Signs and symptoms Lymphatic filariasis Fever Inguinal or axillary lymphadenopathy Testicular and/or inguinal pain Skin exfoliation
More informationCorallopyronin A: a new anti-filarial drug. Kenneth Pfarr Institute for Medical Microbiology, Immunology and Parasitology
Corallopyronin A: a new anti-filarial drug Kenneth Pfarr Institute for Medical Microbiology, Immunology and Parasitology PEG, Weimar, 17 th October, 2014 Filariasis ~150 million people infected >1.3 billion
More informationWHO/FIU Distr.: Limited English only
WHO/FIU98.194 Distr.: Limited English only WHO/FIL/98.194 English only This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document
More informationA SINGLE DOSE OF DOXYCYCLINE IN COMBINATION WITH DIETHYLCARBAMAZINE FOR TREATMENT OF BANCROFTIAN FILARIASIS
A SINGLE DOSE OF DOXYCYCLINE IN COMBINATION WITH DIETHYLCARBAMAZINE FOR TREATMENT OF BANCROFTIAN FILARIASIS Vivornpun Sanprasert 1, Anupong Sujariyakul 2 and Surang Nuchprayoon 1 1 Lymphatic Filariasis
More informationA review of Filariasis
International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Review Article Volume 5, Issue 2-2019 DOI: http://dx.doi.org/10.22192/ijcrms.2019.05.02.005
More informationNewly acquired Onchocerca volvulus filariae after doxycycline treatment
Parasitol Res (2009) 106:23 31 DOI 10.1007/s00436-009-1624-5 ORIGINAL PAPER Newly acquired Onchocerca volvulus filariae after doxycycline treatment Sabine Specht & Achim Hoerauf & Ohene Adjei & Alexander
More informationDrug Discovery: Supporting development of new drugs to treat global parasitic diseases
Drug Discovery: Supporting development of new drugs to treat global parasitic diseases UC Santa Cruz Bio 117 Feb. 23, 2016 Judy Sakanari Center for Parasitic Diseases UC San Francisco Parasitic Diseases,
More informationAlbendazole for the control and elimination of lymphatic filariasis: systematic review
Tropical Medicine and International Health volume 10 no 9 pp 818 825 september 2005 Albendazole for the control and elimination of lymphatic filariasis: systematic review Julia Critchley 1, David Addiss
More informationFilaria Journal. Open Access. Abstract. BioMed Central
Filaria Journal BioMed Central Research Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin Alexander Yaw Debrah
More informationThe symbiotic role of Wolbachia in Onchocercidae and its impact on filariasis
REVIEW 10.1111/1469-0691.12069 The symbiotic role of Wolbachia in Onchocercidae and its impact on filariasis T. Bouchery, E. Lefoulon, G. Karadjian, A. Nieguitsila and C. Martin UMR 7245, MCAM MNHN CNRS,
More informationAlbendazole and antibiotics synergize to deliver short-course anti-wolbachia curative treatments in preclinical models of filariasis
Albendazole and antibiotics synergize to deliver short-course anti-wolbachia curative treatments in preclinical models of filariasis Joseph D. Turner a,1, Raman Sharma a,1, Ghaith Al Jayoussi a, Hayley
More informationM Correia, D Amonkar, P Audi, C Bhat, P Cruz, N Mitta, A Pednekar, P Kurane
ISPUB.COM The Internet Journal of Surgery Volume 25 Number 2 Filariasis In The Arm A Diagnostic Enigma! M Correia, D Amonkar, P Audi, C Bhat, P Cruz, N Mitta, A Pednekar, P Kurane Citation M Correia, D
More informationProgress and challenges in the discovery of macrofilaricidal drugs
Review For reprint orders, please contact reprints@expert-reviews.com Progress and challenges in the discovery of macrofilaricidal drugs Expert Rev. Anti Infect. Ther. 9(8), 681 695 (2011) Timothy G Geary
More informationNo Depletion of Wolbachia from Onchocerca volvulus after a Short Course of Rifampin and/or Azithromycin
Am. J. Trop. Med. Hyg., 77(5), 2007, pp. 878 882 Copyright 2007 by The American Society of Tropical Medicine and Hygiene No Depletion of Wolbachia from Onchocerca volvulus after a Short Course of Rifampin
More informationKraichat.tan@mahidol.ac.th 1 Outline Vector Borne Disease The linkage of CC&VBD VBD Climate Change and VBD Adaptation for risk minimization Adaptation Acknowledgement: data supported from WHO//www.who.org
More informationThe Effect of Compliance on the Impact of Mass Drug Administration for Elimination of Lymphatic Filariasis in Egypt
Am. J. Trop. Med. Hyg., 77(6), 2007, pp. 1069 1073 Copyright 2007 by The American Society of Tropical Medicine and Hygiene The Effect of Compliance on the Impact of Mass Drug Administration for Elimination
More informationNew molecules for parasites of animals and humans
New molecules for parasites of animals and humans XXIX Congress SoIPa Ivan Scandale Origins of DNDi 1999 First meeting to describe the lack of R&D for neglected diseases MSF commits the Nobel Peace Prize
More informationJune, 2004 Journal of Vector Ecology 101
June, 2004 Journal of Vector Ecology 101 The in vitro effect of albendazole, ivermectin, diethylcarbamazine, and their combinations against infective third-stage larvae of nocturnally subperiodic Brugia
More informationTHE CONTROL AND SURVEILLANCE OF FILARIASIS IN HAINAN PROVINCE, CHINA
FILARIASIS IN HAINAN, PR CHINA THE CONTROL AND SURVEILLANCE OF FILARIASIS IN HAINAN PROVINCE, CHINA Hu Xi-min, Wang Shan-qing, Huang Jie-min, Lin Shaoxiong, Tong Chongjin, Li Shanwen and Zhen Wen Hainan
More informationDepartment of Microbio
Fila riae National Institutes t of Health Edward Mitre, MD Department of Microbio ology and Immunology Uniformed Services University of the Health Sciences Februar ry 2011 National Institute of llergy
More informationCitation 熱帯医学 Tropical medicine 33(3). p61-6
NAOSITE: Nagasaki University's Ac Title Author(s) Treatment of Dipetalonema gracile i Sakamoto, Makoto; Fujita, Osamu; Sc Ramona, Rosa S.; Rojas, Antonieta D Citation 熱帯医学 Tropical medicine 33(3). p61-6
More informationDirofilaria. Dirofilaria immitis and D. repens in dog and cat and human infections. Editors Claudio Genchi, Laura Rinaldi, Giuseppe Cringoli
Close window to return to IVIS Dirofilaria Dirofilaria immitis and D. repens in dog and cat and human infections Editors Claudio Genchi, Laura Rinaldi, Giuseppe Cringoli Reprinted in the IVIS website with
More informationNew Insights into the Treatment of Leishmaniasis
New Insights into the Treatment of Leishmaniasis Eric Zini Snow meeting, 14 March 2009 Few drugs available for dogs Initially developed to treat human leishmaniasis, later adopted in dogs None eradicates
More informationEffectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study
Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study Michael A Irvine, Wilma A Stolk, Morgan E Smith, Swaminathan Subramanian, Brajendra K Singh, Gary
More informationPeter J. Weina, PhD, MD, FACP, FIDSA Colonel, Medical Corps, US Army Deputy Commander, WRAIR
Peter J. Weina, PhD, MD, FACP, FIDSA Colonel, Medical Corps, US Army Deputy Commander, WRAIR Patrick Manson -Born Scotland, worked in China for 23 yrs - Pioneer in tropical medicine - Posted to Formosa
More informationWORLD HEATH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS
WORLD HEATH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS NTD-STAG M&E SUB-WORKING GROUP ON DISEASE SPECIFIC INDICATORS MEETING REPORT 2012 LYMPHATIC FILARIASIS THE TASK FORCE FOR GLOBAL
More informationThe comparative susceptibility of male and female and of mature and immature cats to infection with sub-periodic Brugia malayi.
Rev. Biol. Trop., 24 (2): 261-266, 1976 The comparative susceptibility of male and female and of mature and immature cats to infection with sub-periodic Brugia malayi by Adam Ewert* (Received for publication
More informationCURRICULUM VITAE. Piyanan Taweethavonsawat. University, Bangkok, Thailand M.Sc. (Pathobiology) Faculty of Veterinary Medicine,
CURRICULUM VITAE Personal Data Name Piyanan Taweethavonsawat Date of Birth July 11, 1974 Place of Birth Civil status Nationality Bangkok, Thailand Single Thai Academic qualifications 1991-1996 D.V.M. Faculty
More informationModule 6. Monitoring and Evaluation (M&E)
Overview 1) Current situation on NTD drug resistance: Accelerating work in NTDs and lessons from livestock. Reports of reduced efficacy in NTDs: evidence to date. Causes of reduced efficacy other than
More informationEvidence of continued transmission of Wuchereria bancrofti
Evidence of continued transmission of Wuchereria bancrofti and associated factors despite nine rounds of ivermectin and albendazole mass drug administration in Rufiji district, Tanzania CLARER JONES 1,
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationChanging Trends and Issues in Canine and Feline Heartworm Infections
Changing Trends and Issues in Canine and Feline Heartworm Infections Byron L. Blagburn College of Veterinary Medicine Auburn University Canine and feline heartworm diagnostic, treatment and prevention
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationEfficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India
Tropical Medicine and International Health volume 7 no 6 pp 541 548 june 2002 Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India T. R.
More informationTyphoid fever - priorities for research and development of new treatments
Typhoid fever - priorities for research and development of new treatments Isabela Ribeiro, Manica Balasegaram, Christopher Parry October 2017 Enteric infections Enteric infections vary in symptoms and
More informationBIO 221 Invertebrate Zoology I Spring Ancylostoma caninum. Ancylostoma caninum cuticular larval migrans. Lecture 23
BIO 221 Invertebrate Zoology I Spring 2010 Stephen M. Shuster Northern Arizona University http://www4.nau.edu/isopod Lecture 23 Ancylostoma caninum Ancylostoma caninum cuticular larval migrans Order Ascarida
More informationDirofilaria immitis in Cats: Diagnosis and Management *
CE Article #2 Dirofilaria immitis in Cats: Diagnosis and Management * C. Thomas Nelson, DVM a Animal Medical Centers of Northeast Alabama Anniston, Alabama ABSTRACT: Imaging and laboratory studies can
More informationمادة االدوية المرحلة الثالثة م. غدير حاتم محمد
م. مادة االدوية المرحلة الثالثة م. غدير حاتم محمد 2017-2016 ANTIMICROBIAL DRUGS Antimicrobial drugs Lecture 1 Antimicrobial Drugs Chemotherapy: The use of drugs to treat a disease. Antimicrobial drugs:
More informationIvermectin for malaria transmission control
Ivermectin for malaria transmission control Technical consultation meeting report WHO Headquarters Geneva 16 September 2016 Presentation outline Background Rationale for the technical consultation Objectives
More informationIntroduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018
Introduction to Chemotherapeutic Agents Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018 Antimicrobial Agents Substances that kill bacteria without harming the host.
More informationDiurnal variation in microfilaremia in cats experimentally infected with larvae of
Hayasaki et al., Page 1 Short Communication Diurnal variation in microfilaremia in cats experimentally infected with larvae of Dirofilaria immitis M. Hayasaki a,*, J. Okajima b, K.H. Song a, K. Shiramizu
More informationFollow this and additional works at:
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and
More informationLymphatic Filariasis: Transmission, Treatment and Elimination. Wilma Stolk
Lymphatic Filariasis: Transmission, Treatment and Elimination Wilma Stolk Lymphatic Filariasis: Transmission, Treatment and Elimination Lymfatische Filariasis: Transmissie, Behandeling en Eliminatie Proefschrift
More informationnumber Done by Corrected by Doctor Dr Hamed Al-Zoubi
number 8 Done by Corrected by Doctor Dr Hamed Al-Zoubi 25 10/10/2017 Antibacterial therapy 2 د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy Figure 2/ Antibiotics target Inhibition of microbial
More informationANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin
ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria
More informationASSOCIATION OF WOLBACHIA WITH HEARTWORM DISEASE IN CATS AND DOGS
ASSOCIATION OF WOLBACHIA WITH HEARTWORM DISEASE IN CATS AND DOGS By PATRICIA ANN DINGMAN A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
More informationSummary of the Eighteenth Meeting of the International Task Force for Disease Eradication (II) April 6, 2011
Summary of the Eighteenth Meeting of the International Task Force for Disease Eradication (II) April 6, 2011 The Eighteenth Meeting of the International Task Force for Disease Eradication (ITFDE) was convened
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC FOR ANTIMICROBIAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 12 November 2007 EMEA/CVMP/SAGAM/383441/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REVISED GUIDELINE ON THE SPC
More informationIntroduction to Helminthology
Introduction to Helminthology HELMINTHES (WORMS) - Characteristics Eukaryotic, multicellular animals that usually have digestive, circulatory, nervous, excretory, and reproductive systems. Worms with bilateral
More informationElephantiasis. C h r i s t i a n H e s s. N u t r i t i o n R o n V e r n o n
Elephantiasis C h r i s t i a n H e s s N u t r i t i o n 1 0 2 0 R o n V e r n o n 11-29-11 Elephantiasis Elephantiasis or Lymphatic Filariasis is defined by The Journal of Veterinary Medicine Series,
More informationCanine Heartworm Update: What we forgot, what we thought we knew and what we really need to know.
Canine Heartworm Update: What we forgot, what we thought we knew and what we really need to know. Michael W Dryden DVM, MS, PhD, DACVM (parasitology) Department of Diagnostic Medicine/Pathobiology Kansas
More informationAhead of print online version. Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models
FOLIA PARASITOLOGICA 61 [6]: 561 570, 2014 ISSN 0015-5683 (print), ISSN 1803-6465 (online) doi: 10.14411/fp.2014.068 Institute of Parasitology, Biology Centre ASCR http://folia.paru.cas.cz/ Moxidectin
More informationHEARTWORM DISEASE AND THE DAMAGE DONE
HEARTWORM DISEASE AND THE DAMAGE DONE Stephen Jones, DVM There are now more months of the year where environmental conditions favor mosquito survival and reproduction. Warmer temperatures Indoor environments
More informationVector-Borne Diseases & Treatment
Chapter 1 Vector-Borne Diseases & Filariasis: its Manifestations, Epidemiology and Control Strategies Priyanka Rai 1 ; Minu Bharati 1 ; Dhiraj Saha* 1 Insect Biochemistry and Molecular Biology Laboratory,
More informationInfection, Genetics and Evolution
Infection, Genetics and Evolution 14 (2013) 137 146 Contents lists available at SciVerse ScienceDirect Infection, Genetics and Evolution journal homepage: www.elsevier.com/locate/meegid Review Inter and
More informationEFSA Scientific Opinion on canine leishmaniosis
EFSA Scientific Opinion on canine leishmaniosis Andrea Gervelmeyer Animal Health and Welfare Team Animal and Plant Health Unit AHAC meeting 19 June 2015 PRESENTATION OUTLINE Outline Background ToR Approach
More informationUpdate of Oncho Program Status. Kofi Marfo
Update of Oncho Program Status Kofi Marfo Presentation Outline Introduction Progress of Activities Achievements Challenges Way Forward NTDs A group of about 17 infectious diseases which affect over a billion
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationConsiderations in antimicrobial prescribing Perspective: drug resistance
Considerations in antimicrobial prescribing Perspective: drug resistance Hasan MM When one compares the challenges clinicians faced a decade ago in prescribing antimicrobial agents with those of today,
More informationMultiple drug resistance pattern in Urinary Tract Infection patients in Aligarh
Multiple drug resistance pattern in Urinary Tract Infection patients in Aligarh Author(s): Asad U Khan and Mohd S Zaman Vol. 17, No. 3 (2006-09 - 2006-12) Biomedical Research 2006; 17 (3): 179-181 Asad
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Selectan 300 mg/ml solution for injection for cattle and swine. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationHOOKWORM FAQ SHEET (rev ) Adapted from the CDC Fact Sheet
HOOKWORM FAQ SHEET (rev 3-1-10) Adapted from the CDC Fact Sheet Hookworm Infection FAQ Sheet Contents What is hookworm? Where are hookworms commonly found? How do I get a hookworm infection? Who is at
More informationPrinciples of Antimicrobial therapy
Principles of Antimicrobial therapy Laith Mohammed Abbas Al-Huseini M.B.Ch.B., M.Sc, M.Res, Ph.D Department of Pharmacology and Therapeutics Antimicrobial agents are chemical substances that can kill or
More informationSébastien D S Pion*, Cédric B Chesnais*, Gary J Weil, Peter U Fischer, François Missamou, Michel Boussinesq
Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo Sébastien D S
More informationDRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION. Cara Wilder Ph.D. Technical Writer March 13 th 2014
DRUG-RESISTANT ACINETOBACTER BAUMANNII A GROWING SUPERBUG POPULATION Cara Wilder Ph.D. Technical Writer March 13 th 2014 ATCC Founded in 1925, ATCC is a non-profit organization with headquarters in Manassas,
More informationHeartworm Disease in Dogs
Customer Name, Street Address, City, State, Zip code Phone number, Alt. phone number, Fax number, e-mail address, web site Heartworm Disease in Dogs Basics OVERVIEW Disease caused by infestation with heartworms
More informationMarkers for benzimidazole resistance in human parasitic nematodes?
Markers for benzimidazole resistance in human parasitic nematodes? 1087 ROGER K. PRICHARD* Institute of Parasitology, McGill University, 21111 Lakeshore Road, Ste-Anne-de-Bellevue, Quebec, Canada, H9X
More informationSUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT NUFLOR 300 mg/ml solution for injection for cattle and sheep 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains:
More informationAntimicrobial Selection to Combat Resistance
Antimicrobial Selection to Combat Resistance (Dead Bugs Don t Mutate!) Shelley C Rankin PhD Associate Professor CE Microbiology Head of Diagnostic Services & Chief of Clinical Microbiology Ryan Veterinary
More informationCreating a global community for clinical drug repurposing and development. Leonard Sacks Center for drug evaluation and research FDA
Creating a global community for clinical drug repurposing and development Leonard Sacks Center for drug evaluation and research FDA Neglected tropical diseases 1) Repurposing and developing new drugs 2)
More informationANTIBIOTIC SENSITIVITY PATTERN OF YERSINIA ENTEROCOLITICA ISOLATED FROM MILK AND DAIRY PRODUCTS*
Short Communication ANTIBIOTIC SENSITIVITY PATTERN OF YERSINIA ENTEROCOLITICA ISOLATED FROM MILK AND DAIRY PRODUCTS* T.R.Pugazhenthi 1, A. Elango 2, C. Naresh Kumar 3, B. Dhanalakshmi 4 and A. Bharathidhasan
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationThe Biology and Control of Human Onchocerciasis Prof. Emeritus Ed Cupp
The Biology and Control Professor Emeritus, Ed Cupp Vector Biology Laboratory Depart. of Entomology & Plant Pathology Auburn University, Auburn, AL 1 Life cycle of Onchocerca volvulus*, the causative agent
More informationConsequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationMID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance
Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation
More informationRECENT TRENDS IN TREATMENT AND MANAGEMENT OF FILARIASIS
ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 8 (Review Article) Received on 26 March, 2010; received in revised form 28 June, 2010; accepted 17 July, 2010 RECENT TRENDS IN TREATMENT AND MANAGEMENT OF FILARIASIS
More informationLYMPHATIC FILARIASIS WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS. A HanDbook for national elimination programmes
WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS Lymphatic filariasis: PRACTICAL ENTOMOLOGY LYMPHATIC FILARIASIS A HanDbook for national elimination programmes WORLD HEALTH
More informationVICH Topic GL20 EFFICACY OF ANTHELMINTICS: SPECIFIC RECOMMENDATIONS FOR FELINE
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology CVMP/VICH/545/00-FINAL London, 30 July 2001 VICH Topic GL20 Step 7 EFFICACY OF ANTHELMINTICS:
More informationAn#bio#cs and challenges in the wake of superbugs
An#bio#cs and challenges in the wake of superbugs www.biochemj.org/bj/330/0581/bj3300581.htm ciss.blog.olemiss.edu Dr. Vassie Ware Bioscience in the 21 st Century November 14, 2014 Who said this and what
More informationPotential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of
VIEWPOINTS Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa Peter U. Fischer
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationMolecular Diagnosis and Monitoring of Benzimidazole Susceptibility of Human Filariids
23 Molecular Diagnosis and Monitoring of Benzimidazole Susceptibility of Human Filariids Adisak Bhumiratana 1,2,3, Apiradee Intarapuk 3, Danai Sangthong 3, Surachart Koyadun 4, Prapassorn Pechgit 1 and
More informationHow Animal Shelters Can Treat and Prevent Heartworm in Dogs August 28, 2014
Practical Management of Canine Heartworm Disease in Animal Shelters Brian A. DiGangi, DVM, MS, DABVP (Canine/Feline) Clinical Assistant Professor Veterinary Community Outreach Program College of Veterinary
More informationSelective toxicity. Antimicrobial Drugs. Alexander Fleming 10/17/2016
Selective toxicity Antimicrobial Drugs Chapter 20 BIO 220 Drugs must work inside the host and harm the infective pathogens, but not the host Antibiotics are compounds produced by fungi or bacteria that
More informationAntimicrobial agents. are chemicals active against microorganisms
Antimicrobial agents are chemicals active against microorganisms Antibacterial Agents Are chemicals active against bacteria Antimicrobials Antibacterial Antifungal Antiviral Antiparasitic: -anti protozoan
More informationMosquitoes and Heartworm Disease: The Forgotten Culprit (in a Deadly Disease)
RACE-Approved, 1 Hour CE Course Continuing Education by Ceva Animal Health Mosquitoes and Heartworm Disease: The Forgotten Culprit (in a Deadly Disease) AUTHOR: CHADD DODD, DVM Chapter One A New Way to
More informationModule 1. Introduction to Targeted Neglected Tropical Diseases (NTDs)
TARGETED FOR CONTROL OR Module 1. Introduction to Targeted Neglected Tropical Diseases (NTDs) Overview Road map to NTDs targeted for Preventive Chemotherapy (PC) Disease specific epidemiology and control
More informationElimination of Lymphatic Filariasis in the South-East Asia Region
Elimination of Lymphatic Filariasis in the South-East Asia Region Report of the Ninth Meeting of the Regional Programme Review Group (RPRG) Yangon, Myanmar, 30 April 1 May 2012 Regional Office for South-East
More informationReceived: Accepted: Access this article online Website: Quick Response Code:
Indian Journal of Drugs, 2016, 4(3), 69-74 ISSN: 2348-1684 STUDY ON UTILIZATION PATTERN OF ANTIBIOTICS AT A PRIVATE CORPORATE HOSPITAL B. Chitra Department of Pharmacy Practice, College of Pharmacy, Sri
More informationAntimicrobial Resistance
Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length
More informationAntimicrobial Resistance Acquisition of Foreign DNA
Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple
More informationLymphatic Filariasis Elimination Programme
Lymphatic Filariasis Elimination Programme training module for drug distributors in countries where lymphatic filariasis is not co-endemic with onchocerciasis World Health Organization Part 1. Lymphatic
More informationAntibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus
B-O-021 Antibacterial activity of Stephania suberosa extract against methicillin-resistant Staphylococcus aureus Nongluk Autarkool *a, Yothin Teethaisong a, Sajeera Kupittayanant b, Griangsak Eumkeb a
More informationModern Parasitology For The Cat:
Modern Parasitology For The Cat: Fleas, Mites, and Worms, Oh My! Annette Litster BVSc PhD FACVSc (Feline Medicine) MMedSci (Clinical Epidemiology) Senior Veterinary Specialist, Zoetis Chris Adolph DVM,
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationVisit ABLE on the Web at:
This article reprinted from: Lessem, P. B. 2008. The antibiotic resistance phenomenon: Use of minimal inhibitory concentration (MIC) determination for inquiry based experimentation. Pages 357-362, in Tested
More informationThe ways in which bacteria resist antibiotics
International Journal of Risk & Safety in Medicine 17 (2005) 111 116 111 IOS Press The ways in which bacteria resist antibiotics Dan I. Andersson Uppsala University, Department of Medical Biochemistry
More information